CPGJ-602 / 3SBio - LARVOL DELTA

CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study. (ASCO 2022) - P2 | "CPGJ602 plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) may have efficacy in KRAS/NRAS/BRAF wild-type metastatic colorectal cancer. CPGJ602 plus mFOLFOX6 could be an option for KRAS/NRAS/BRAF wild-type metastatic colorectal cancer."

Clinical • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (clinicaltrials.gov) - P2; N=75; Recruiting; Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2021 ➔ Mar 2022; Trial primary completion date: Aug 2021 ➔ Dec 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS

Guojian cleared for Phase Ib/II study for CPGJ602 plus inetetamab combo in CRC (GBI Health) - "China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc., (HKEX:1530) announced receiving the go-ahead from the National Medical Products Administration to initiate a Phase Ib/II clinical study for its anti-EGFR monoclonal antibody CPGJ602 combined with inetetamab plus chemotherapy in HER2-positive metastatic colorectal cancer (CRC) with wild-type KRAS, NRAS, and BRAF."

New P1/2 trial • Non-US regulatory • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (clinicaltrials.gov) - P2; N=75; Not yet recruiting; Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Clinical • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS